Origin: Human prostate cancer, derived from CWR22R xenograft
Characteristics: Epithelial-like, adherent growth, androgen receptor-positive, expresses chimeric AR-V7 splice variant
Applications: Used in prostate cancer research, castration-resistant prostate cancer (CRPC) studies, and drug development. Valuable for investigating the role of genes in AR signaling, therapy resistance, and bone metastasis.
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO00225 | ZBTB33 Knockout cell line (22Rv1) | Human | ZBTB33 | 1:2~1:3 | Negative | Online Inquiry |
KO00777 | ATM Knockout cell line(22Rv1) | Human | ATM | 1:2~1:3 | Negative | Online Inquiry |
KO00788 | PRDX5 Knockout cell line(22Rv1) | Human | PRDX5 | 1:2~1:3 | Negative | Online Inquiry |
KO00815 | NQO1 Knockout cell line(22Rv1) | Human | NQO1 | 1:2~1:3 | Negative | Online Inquiry |
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.